NasdaqGM:ZLABBiotechs
Zai Lab AACR Update Puts Internal Oncology Pipeline And Global Aims In Focus
Zai Lab (NasdaqGM:ZLAB) plans to present data on three internally developed oncology therapies at the AACR Annual Meeting 2026.
The pipeline includes a DLL3 targeting antibody drug conjugate for small cell lung cancer and an immunocytokine for solid tumors such as sarcoma.
One candidate, zoci, is described by the company as being on track for its first global oncology launch.
The presentations highlight progress in late stage clinical development and Zai Lab’s intentions to pursue...